Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that duvelisib maintenance after autologous stem cell
transplant with carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning in
patients with T-cell lymphomas, or a history of indolent B-cell lymphomas, will be safe and
well tolerated, and will improve progression free survival.